PE20161315A1 - Compuestos de pirazolona y usos de los mismos - Google Patents

Compuestos de pirazolona y usos de los mismos

Info

Publication number
PE20161315A1
PE20161315A1 PE2016001440A PE2016001440A PE20161315A1 PE 20161315 A1 PE20161315 A1 PE 20161315A1 PE 2016001440 A PE2016001440 A PE 2016001440A PE 2016001440 A PE2016001440 A PE 2016001440A PE 20161315 A1 PE20161315 A1 PE 20161315A1
Authority
PE
Peru
Prior art keywords
compounds
optionally substituted
pyrazol
phenoxy
dihydro
Prior art date
Application number
PE2016001440A
Other languages
English (en)
Inventor
Yalda Mostofi Bravo
Austin Chih-Yu Chen
Yen Truong
Nicholas Simon Stock
Jason Duarte Jacintho
Original Assignee
Inception 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53800550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inception 2 Inc filed Critical Inception 2 Inc
Publication of PE20161315A1 publication Critical patent/PE20161315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula I o sales farmaceuticamente aceptables de los mismos, donde: R1 y R2 son cada uno -C1-6 alquilo o CH3 opcionalmente sustituidos por halogeno o R1 y R2 forman juntos -C3-6 cicloalquilo opcionalmente sustituido por halogeno, C1-6 alquilo y -CF3; R3 es un arilo, heteroarilo opcionalmente sustituido, entre otros; R4 es un heteroarilo, -C1-2alquilo-arilo, opcionalmente sustituido, entre otros. Son compuestos preferidos: acido 2-(4-(3-(1-(4-(ter-butil)bencil)-4,4-dimetil-5-oxo-4,5-dihidro-1H-pirazol-3-il)propil)fenoxi)-2-metilpropanoico; 2-(4-(3-(1-(4-(ter-butil)bencil)-4,4-dimetil-5-oxo-4,5-dihidro-1H-pirazol-3-il)propil)fenoxi)-2-metil-N-(fenilsulfonil)propanamida, entre otros. Tambien se refiere a una composicion y un metodo de tratamiento. Dichos compuestos actuan como antagonistas selectivos del peroxisoma proliferador activado del receptor a (PPARalfa) siendo utiles en el tratamiento de cancer de prostata, mama, entre otros, e infecciones virales tales como VIH y VHC
PE2016001440A 2014-02-14 2015-02-09 Compuestos de pirazolona y usos de los mismos PE20161315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461939955P 2014-02-14 2014-02-14

Publications (1)

Publication Number Publication Date
PE20161315A1 true PE20161315A1 (es) 2016-12-25

Family

ID=53800550

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001440A PE20161315A1 (es) 2014-02-14 2015-02-09 Compuestos de pirazolona y usos de los mismos

Country Status (16)

Country Link
US (2) US9862708B2 (es)
EP (1) EP3105205A4 (es)
JP (1) JP2017505804A (es)
KR (1) KR20160115996A (es)
CN (1) CN106029640B (es)
AU (1) AU2015217450A1 (es)
BR (1) BR112016017781A2 (es)
CA (1) CA2937542A1 (es)
EA (1) EA201691342A1 (es)
IL (1) IL247148A0 (es)
MX (1) MX2016010436A (es)
NZ (1) NZ722345A (es)
PE (1) PE20161315A1 (es)
SG (1) SG11201606149YA (es)
WO (1) WO2015123133A1 (es)
ZA (1) ZA201605222B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11572369B2 (en) * 2019-02-01 2023-02-07 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
BR112022019987A2 (pt) 2020-04-07 2022-11-22 Bayer Ag Tiazolpiridinas substituídas, seus sais e uso dos mesmos como substâncias herbicidamente ativas
WO2022194843A1 (en) 2021-03-19 2022-09-22 Bayer Aktiengesellschaft Substituted 1,2,4-thiadiazoles, salts thereof and their use as herbicidally active substances
AR125453A1 (es) 2021-04-27 2023-07-19 Bayer Ag Piridazinonas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas
WO2023020964A1 (en) 2021-08-17 2023-02-23 Bayer Aktiengesellschaft Substituted 1,2,4-thiadiazolyl nicotinamides, salts or n-oxides thereof and their use as herbicidally active substances
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
AR127618A1 (es) 2021-11-29 2024-02-14 Bayer Ag Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas
EP4238972A1 (en) 2022-03-04 2023-09-06 Bayer AG Substituted 1,2,4-thiadiazolyl picolinamides, salts or n-oxides thereof and their use as herbicidally active substances
EP4238973A1 (en) 2022-03-04 2023-09-06 Bayer AG Substituted 1,2,4-thiadiazolyl isonicotinamides, salts or n-oxides thereof and their use as herbicidally active substances

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244593A (en) 1963-06-12 1966-04-05 Endo Lab Pharmaceutically active substituted 5-pyrazolones
US4719175A (en) 1982-05-03 1988-01-12 Polaroid Corporation Novel pyrazole compounds having silver halide development groups
DE3312581A1 (de) * 1983-04-08 1984-10-11 Bayer Ag, 5090 Leverkusen Verwendung von pyrazolonderivaten bei der bekaempfung des wachstums von tumorzellen und der metastasenbildung, arzneimittel hierfuer und verfahren zu deren herstellung
JPH02229168A (ja) 1989-03-01 1990-09-11 Takeda Chem Ind Ltd ピラゾロン誘導体
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US5484940A (en) 1994-11-28 1996-01-16 Grant; Francine S. Substituted 3-indolyl-5-pyrazolone compounds
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
JP2003506368A (ja) 1999-07-30 2003-02-18 バスフ アクチエンゲゼルシヤフト ２−ピラゾリン−５−オン
US7060822B1 (en) 1999-07-30 2006-06-13 Abbott Gmbh & Co. Kg 2-pyrazolin-5-ones
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
AU2005322173A1 (en) 2004-12-27 2006-07-06 Astrazeneca Ab Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
WO2006129587A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
WO2006129583A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体
MX2009001710A (es) 2006-08-18 2009-02-25 Syngenta Ltd Uso de inhibidores hppd para el tratamiento de la depresion y/o sindrome de abstinencia asociados con drogas adictivas.
KR20090031331A (ko) 2007-09-21 2009-03-25 주식회사 엘지생명과학 옥소 디하이드로 피라졸을 포함하는 신규한 베타 세크리타제 저해용 화합물
EP2367798B1 (en) 2008-11-20 2018-02-28 Northwestern University Pyrazolone derivatives useful in the treatment of amyotrophic lateral sclerosis
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
BR112013015774A2 (pt) 2010-12-01 2018-05-22 Nissan Chemical Industries Ltd compostos de pirazol tendo efeito terapêutico sobre mieloma múltiplo.
WO2012074068A1 (ja) 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
US9505728B2 (en) * 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof

Also Published As

Publication number Publication date
US20170174666A1 (en) 2017-06-22
AU2015217450A1 (en) 2016-08-11
CN106029640B (zh) 2018-08-24
WO2015123133A1 (en) 2015-08-20
CN106029640A (zh) 2016-10-12
US20180079745A1 (en) 2018-03-22
EA201691342A1 (ru) 2016-12-30
NZ722345A (en) 2018-02-23
BR112016017781A2 (pt) 2017-08-08
KR20160115996A (ko) 2016-10-06
MX2016010436A (es) 2016-10-31
AU2015217450A8 (en) 2016-09-08
ZA201605222B (en) 2019-02-27
JP2017505804A (ja) 2017-02-23
EP3105205A4 (en) 2017-08-02
EP3105205A1 (en) 2016-12-21
US9862708B2 (en) 2018-01-09
CA2937542A1 (en) 2015-08-20
IL247148A0 (en) 2016-09-29
SG11201606149YA (en) 2016-09-29

Similar Documents

Publication Publication Date Title
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
EA201691853A1 (ru) Агонисты мускариновых рецепторов
AR094997A1 (es) Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CY1124059T1 (el) Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
BR112018001017A2 (pt) inibidores do receptor de fator-1 de estimulação de colônia (csf-1r)
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20181319A1 (es) Compuestos de isoindol
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
PE20160050A1 (es) Inhibidores/ antiandrogenos novedosos de cyp17
EA201791226A1 (ru) Композиции, содержащие 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения шизофрении
EA201600436A1 (ru) Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
AR101036A1 (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
PE20160666A1 (es) Derivados de etinilo

Legal Events

Date Code Title Description
FD Application declared void or lapsed